Today's Must Read
Microsoft's (MSFT) HoloLens Now Available in 6 New Markets
Thermo Fisher (TMO) Strong on Buyout Synergy, Global Growth
Thursday, October 13, 2016
We are featuring 16 new research reports in today's Research Daily, including analyst-written reports on buy-rated Caterpillar (CAT), Microsoft (MSFT) and Thermo Fisher (TMO).
Caterpillar shares have struggled over the last few years as a result of the commodity bust and weak global spending on infrastructure and construction. But after bottoming earlier this year, the stock has had an impressive run up (up more than 28% year-to-date), with improving outlook for construction activities and management efforts to improve efficiencies and squeeze costs out of operations finally getting acknowledged. While the outlook for mining continues to be problematic, the construction has started showing signs of life, as recent data from the Asia Pacific region show. This is starting to show up in rising EPS estimates for this buy-rated stock. (You can read the full research report on Caterpillar here>>)
Microsoft shares have lagged the Tech sector and the broader market this year (the stock is up about 3% year-to-date), given continued headwinds in the PC space that has weighed on the Windows 10 adoption rates. But the company's efforts to reorganize and reposition its businesses hold long-term promise. Microsoft's cloud opportunity particularly stands out, with the company appearing to be emerging as a leader in this fast-growing space, alongside Amazon, Google's parent Alphabet and others. The Zacks analyst also likes buy-rated Microsoft's enterprise strength, the Office 365 subscription model, Azure and promising new products in the augmented and virtual reality space. (You can read the full research report on Microsoft here>>)
Thermo Fisher shares have outperformed the broader medical sector (up more than 8% year-to-date), with the recently completed FEI Company acquisition expected to significantly facilitate the company’s performance in life-science research. The FEI acquisition followed the successful purchase and integration of Affimetrix that boosted the buy-rated Thermo Fisher's offerings in the fast-growing flow cytometry market. Fresh product launches, strong growth in emerging markets and an enhancement in the company’s customer value proposition are other positives. (You can read the full research report on Thermo Fisher here>>)
Other noteworthy reports we are featuring today include Alcoa (AA), Baxter (BAX) and PNC Financial (PNC).
Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
You can find all of today's stock research reports here>>
Director of Research